Equibles does not estimate personal net worth.
Get an email with a short summary when Thermo Fisher Scientific Inc. publishes a filing, an earnings call transcript or a press release.
Get TMO alertsJames R. Meyer is recorded as CFO at Thermo Fisher Scientific Inc. (TMO) since March 1, 2026. Thermo Fisher Scientific Inc. reported in an 8-K filed July 23, 2025 that James R. Meyer was appointed Senior Vice President and CFO of the Company, effective March 1, 2026. James R. Meyer has spoken on 3 earnings calls and 1 other investor event across 1 company, most recently for Thermo Fisher Scientific Inc. on October 21, 2026. Thermo Fisher Scientific Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at Thermo Fisher Scientific Inc. includes Marc Casper (CEO), Marc N. Casper (CEO and Board Member), Gianluca Pettiti (COO) and 7 others.
“The Company also announced that the Board of Directors approved the appointment of James R. Meyer, 46, currently Vice President, Financial Operations of the Company, to succeed Williamson as Senior Vice President and CFO of the Company, effective March 1, 2026.”
“I'll take you through an overview of our third quarter results for the total company and then provide color on our four business segments. And finally, I'll provide details on our updated guidance for the year.”
“I'll take you through an overview of our second quarter results for the total company and then provide color on our four business segments and conclude with details on our updated guidance for the year.”
“One of the constants in my 17 plus years with the company is the PPI business system. I vividly remember sorry I vividly remember my initial PPI training upon joining the company that included a competitive simulation on most efficiently making toast.”
“I'll start by thanking Mark and Stephen for their support during my transition into the role. I've appreciated meeting many of you on the call over the past few months and look forward to continued engagement with the investor community.”
2026-03-01–present
Diagnostics & Research · Healthcare
CFO
2026-03-01–present
